Envista Holdings Co. (NYSE:NVST) Holdings Decreased by Diamond Hill Capital Management Inc.

Diamond Hill Capital Management Inc. reduced its stake in shares of Envista Holdings Co. (NYSE:NVST) by 25.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 998,612 shares of the company’s stock after selling 337,098 shares during the quarter. Diamond Hill Capital Management Inc. owned about 0.58% of Envista worth $19,263,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Pacer Advisors Inc. grew its holdings in Envista by 22.2% during the third quarter. Pacer Advisors Inc. now owns 3,529,827 shares of the company’s stock worth $69,749,000 after acquiring an additional 642,401 shares during the period. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Envista during the fourth quarter worth about $53,000. Lecap Asset Management Ltd. acquired a new position in Envista during the fourth quarter worth about $281,000. Hotchkis & Wiley Capital Management LLC acquired a new position in Envista during the third quarter worth about $14,965,000. Finally, Geode Capital Management LLC grew its holdings in Envista by 2.5% during the third quarter. Geode Capital Management LLC now owns 2,895,653 shares of the company’s stock worth $57,233,000 after acquiring an additional 71,435 shares during the period.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Wells Fargo & Company set a $19.00 target price on Envista in a report on Saturday, March 8th. JPMorgan Chase & Co. lowered their target price on Envista from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Thursday, March 6th. Mizuho began coverage on Envista in a research note on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price target on the stock. UBS Group dropped their price target on Envista from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Monday, March 10th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Envista in a research note on Thursday, March 6th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $20.18.

Envista Trading Up 2.3 %

NYSE:NVST opened at $16.63 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. Envista Holdings Co. has a fifty-two week low of $15.15 and a fifty-two week high of $23.00. The stock’s 50-day moving average is $19.99 and its two-hundred day moving average is $19.63. The stock has a market cap of $2.86 billion, a PE ratio of -2.56, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33.

Envista (NYSE:NVST) last released its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. As a group, equities research analysts forecast that Envista Holdings Co. will post 1 earnings per share for the current fiscal year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.